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Abstract
Background: According to the very limited cancer registry, incidence and mortality rates for female breast cancer
in China are regarded to be increasing especially in the metropolitan areas. Representative data on the breast
cancer profile of Chinese women and its time trend over years are relatively rare. The aims of the current study are
to illustrate the breast cancer profile of Chinese women in time span and to explore the current treatment
approaches to female breast cancer.
Methods: This was a hospital-based nation-wide and multi-center retrospective study of female primary breast
cancer cases. China was divided into 7 regions according to the geographic distribution; from each region, one
tertiary hospital was selected. With the exception of January and February, one month was randomly selected to
represent each year from year 1999 to 2008 at every hospital. All inpatient cases within the selected month were
reviewed and related information was collected based on the designed case report form (CRF). The Cancer
Hospital/Institute, Chinese Academy of Medical Sciences (CICAMS) was the leading hospital in this study.
Results: Four-thousand two-hundred and eleven cases were randomly selected from the total pool of 45,200
patients and were included in the analysis. The mean age at diagnosis was 48.7 years (s.d. = 10.5 yrs) and breast
cancer peaked in age group 40-49 yrs (38.6%). The most common subtype was infiltrating ductal carcinoma
(86.5%). Clinical stage I & II accounted for 60.6% of 4,211 patients. Three-thousand five-hundred and thirty-four
cases had estrogen receptor (ER) and progestin receptor (PR) tests, among them, 47.9% were positive for both.
Two-thousand eight-hundred and forty-nine cases had human epidermal growth factor receptor 2(HER-2) tests,
25.8% of them were HER-2 positive. Among all treatment options, surgery (96.9% (4,078/4,211)) was predominant,
followed by chemotherapy (81.4% (3,428/4,211). Much less patients underwent radiotherapy (22.6% (952/4,211))
and endocrine therapy (38.0% (1,599/4,211)).
Conclusions: The younger age of breast cancer onset among Chinese women and more advanced tumor stages
pose a great challenge. Adjuvant therapy, especially radiotherapy and endocrine therapy are of great unmet needs.
Background
Breast cancer is the second most common cancer world-
wide today, and by far the most common cancer in
women in many countries, with an estimated 1.4 million
new cases and 458,000 deaths around 2008 annually [1].
Although breast cancer incidence and mortality rates in
the western countries have been decreasing or stable dur-
ing the past 2 to 3 decades, both rates have been increas-
ing rapidly in many developing countries [2]. In China,
according to the most updated but limited cancer regis-
tries, breast cancer became the most important incident
female cancer and ranked the 6
th leading cause of death in
Chinese women in year 2006 [3]. No nation-wide repre-
sentative data of breast cancer in China was available.
The etiology of breast cancer remains unknown. Due
to the lack of evidence, primary preventive strategies for
* Correspondence: Qiaoy@cicams.ac.cn
1Dept. of Cancer Epidemiology, Cancer Institute & Hospital, Chinese
Academy of Medical Sciences & Peking Union Medical College, 17 South
Panjiayuan Lane, Beijing 100021, China
Full list of author information is available at the end of the article
Li et al. BMC Cancer 2011, 11:364
http://www.biomedcentral.com/1471-2407/11/364
© 2011 Li et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.breast cancer have commanded little attention. Rather,
the focus has been on improving prognosis (outcome)
for women developing breast cancer, through early
detection and improved treatment (surgical, radiother-
apy, hormonal and chemotherapeutic measures). Cur-
rent therapeutic options for breast cancer in China are
varied, with treatment allocation generally dependent on
the accessible resources, the patient’s economic status
and the tumor burden. In the recent decades, when
estrogen receptor (ER) status was approved to be an
important treatment and prognostic factor, targeted
therapy has become encouraging in breast cancer treat-
ment [4]. But due to limited access of updated guide-
lines and resources, information regarding the
application of breast cancer treatment with this new
therapy within China is not clear.
The nation-wide multi-center 10-year (1999-2008) ret-
rospective clinical epidemiological study of female breast
Cancer in China was a retrospective study of patients
with pathology confirmed primary breast cancer from 7
geographic regions across China (North, North-East,
Central, South, East, North-West, and South-West). The
aims of this study were to document (1) the sociodemo-
graphic characteristics and the distribution of some risk
factors among Chinese female breast cancer cases; (2) the
clinical characteristics of female breast cancer and (3)
current treatment options for Chinese female breast can-
cer patients.
Methods
Study Design
This study was a hospital-based multi-center 10 year ret-
rospective study of randomly selected pathology con-
firmed primary female breast cancer cases via medical
chart review.
Selection of Regions and Hospitals
As described previously, China was stratified into 7 geo-
graphic regions according to the traditional administrative
district definition; these regions extend over the majority
of the country and represent different levels of breast can-
cer burden. One tertiary hospital from each region was
selected to provide the required study cases.
Convenient sampling was used to choose the partici-
pant hospitals with inclusion in the study on the basis
that (1) they were one of the best leading hospitals at the
tertiary level and had regional referral centers providing
pathology diagnosis, surgery, radiotherapy, medical
oncology, and routine follow-up care for patients with
breast cancer; (2) visiting patients were from different
parts of the region; and (3) the breast cancer screening
practices, when used, should be in accordance with Chi-
nese national standards. A total of 7 hospitals were
involved in the study, with Cancer Hospital/Institute,
Chinese Academy of Medical Sciences (CICAMS) as the
lead center for the overall coordination of this research
in China [Figure 1].
Patients
This study included pathology confirmed female primary
breast cancer inpatients in one randomly selected month
each from year 1999 to 2008. January and February were
excluded for randomization because Chinese traditional
spring festival is always in these two months and there
are much fewer inpatients during the time period. In
order to avoid selection bias, an enrolment scheme was
adopted using alternating prespecified month of inpatient
admission from year to year. For example, in the first
year (1999) of data collection, pathology confirmed pri-
mary breast cancer patients admitted to inpatient treat-
ment in March would be enrolled into the study; in the
second year (2000), inpatients admitted in April would
be enrolled. All cases within the selected month were
reviewed and patient’s information was collected based
on the designed case report form (CRF). In each selected
month, if inpatients admissions were less than 50 in that
year, more cases from the neighbouring months were
reviewed until the total number in that year reaches 50.
Whereas, if inpatients number in the selected month
exceeded 50, all cases should be reviewed. To ensure that
the national study was geographically representative, it
was designed to include patients enrolled at sites from all
7 traditional regions across China [Figure 1].
All patients enrolled in this study must meet 3 key
inclusion criteria: (1) pathology confirmed primary
breast cancer (2) inpatient admission date was within
the selected month in the study hospital and (3)
received or receiving treatment (surgery, medical oncol-
ogy, radiotherapy) for breast cancer.
This study was approved by the Cancer Foundation of
China Institutional Review Board. Patient consent was
not required for this study because there were no antici-
pated risks for the participants of the study. The data was
stripped of any patient identifiers per the approved pro-
cedures. De-identified data were maintained on secure
database. Only research team members have access to
the data. All data will be reported in aggregate.
Pathologic Diagnostic Criteria
Histological subtype was based on the 1981 and 2003
WHO histological classification criteria [5,6]. Staging of
breast cancer was done according to the AJCC TNM
staging system of year 1997 and after [7,8].
Data Collection and Quality Control
The following data were systematically collected for all
enrolled patients via medical chart review: (1) general
information including date of diagnosis, visits to other
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nosis at admission, inpatient discharge date, and dis-
charge outcome; (2) demographic characteristics at the
time of diagnosis/admissions including age, occupation,
height, weight, education and marital status; (3) breast
cancer risk factors such as age at menarche, age at
menopause, age at marriage, age at first delivery, num-
ber of live birth, breastfeeding history, family history of
breast cancer, use of oral contraception, history of
smoking and alcohol drinking; (4) results of the clinical
breast examination (CBE); (5) results of the diagnostic
imaging including mammography, ultrasound and mag-
netic resonance imaging (MRI); (6) the use of currently
available surgery approaches; (7) the use of radiotherapy
for breast cancer; (8) the use of chemotherapy for breast
cancer, including adjuvant chemotherapy and neoadju-
vant chemotherapy; (9) the use of molecular targeted
therapy for breast cancer; (10) pathological characteris-
tics including pre-surgery cytology and pathologic exam-
inations, intraoperative pathologic evaluation, post-
surgery pathology, estrogen and progesterone receptor
expressions and human epidermal growth factor recep-
tor 2(HER-2) expression etc. Also, the ranking and
number of the 10 most dominant cancer patients visits
were also collected.
All above information was extracted from medical
charts to the designed CRF by local clerks after training.
Then two data input clerks from each site were recruited
to independently double-enter data from the paper to
computer based database (FoxPro). All finished double-
entry databases were sent to CICAMS for validation by
running EpiData. Any inconsistency found by CICAMS
between the two databases was reported to the local
clerks for adjudication until the databases agreed. As a
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Figure 1 Geographic distribution of sites included in the study. 1: Cancer Institute/ Hospital, Chinese Academy of Medical Sciences 2:
Liaoning Cancer Hospital 3: Second Xiangva Hospital, Central South University 4: Guangdong Sun Yat-Sen University Cancer Center 5: Zhejiang
Cancer Hospital 6: First Affiliated Hospital of Xi’an Jiaotong University 7: Sichuan Cancer Hospital.
Li et al. BMC Cancer 2011, 11:364
http://www.biomedcentral.com/1471-2407/11/364
Page 3 of 11final inspection, one of databases was chosen to undergo
a final consistency check. Logical errors (e.g. a woman
had no surgery yet had intraoperative frozen section
diagnosis) were again reported back to the local sites, and
the local collaborators reviewed the original medical
chart again. After checking with the original medical
record, the local staff sent the revised database back to
CICAMS for a final analysis. During the consistency
check, 5% of the medical charts were randomly selected
based on the study ID and sent to CICAMS for quality
control review.
Sample Size
Sample size requirements for the Chinese regional sites
were a minimum of 50 patients per site per year
between 1999 and 2008. To capture treatment and clini-
cal outcomes in breast cancer over 10 years, it was man-
datory to collect a total number of no less than 500
cases per hospital in time span. Pooling of data across
all sites in China was employed to adequately describe
disease and treatment characteristics across the country.
Data Analysis
Frequencies were run on variables related to demo-
graphic, reproductive, clinical and pathologic characteris-
tics to determine their distribution overall and among
early stage (ES) (stage I & II) compared to late stage (LS)
(stage III & IV). Quantitative variables were calculated by
the mean or median depending on the data distribution.
The differences in distribution of variables between ES
and LS were examined using Mantel-Haenszel chi-square
tests and Fisher’se x a c tt e s t st oo b t a i np-values for the
test of no-association.
SPSS statistical software version 17.0 was used to ana-
lyze the data. Statistical significance was assessed by
two-tailed tests with a level of 0.05.
Results
A total number of 4,267 breast cancer inpatients across
the various geographic regions in the study were col-
lected. Of them, 48 cases were excluded for analysis
because they were not from the selected months. Seven
were deleted because the final pathological diagnoses
belonged to benign tumors instead of malignancy. One
case was disqualified because the ‘unknown’ items
exceeded 50% of the CRF. A final total number of 4,211
cases from seven sites across China were included for
final analysis. Table 1 illustrates the case distribution and
proportion by region and year.
Patients Characteristics
Of the total 4,211 cases that were identified over a per-
iod of 10 years from 1999 to 2008, the mean age at
diagnosis and age range for all breast cancer patients
was 48.7 years (s.d. = 10.5 yrs) and 21-86 years, respec-
tively. Among all cases, 2,554 (60.6%) were in ES with a
mean age of 49.1 years (s.d. = 10.4 yrs) while 901
(21.4%) were in LS with a mean age of 48.8 years (s.d. =
10.3 yrs). The majority (67.6%) of breast cancer patients
were of normal Body Mass Index (BMI). More breast
cancer cases presented in LS (59.6%) were manual work-
ers (P < 0.001) and the proportion of receiving higher
education (university and above) was much less com-
pared with the ES group (14.2% vs. 21.3%, P = 0.008).
The percentage distribution of smoking, alcohol drink-
ing and family history of breast cancer differed between
women presented in ES and LS (P < 0.050) (Table 2).
More breast cancer cases (7.6% vs. 6.3%. P = 0.030) pre-
sented in LS reported to have the first delivery at or
older than 30 years of age and the percentage distribu-
tion of self reported oral contraceptive use differed
between women presented in ES and LS (P < 0.001)
(Table 3).
Table 1 Case distribution by region and year
Year North North-East Central South East North-West South-West Total
N* n**(%) N* n**(%) N* n**(%) N* n**(%) N* n**(%) N* n**(%) N* n**(%) N* n**(%)
2008 1649 91(5.5) 1632 82(5.0) 647 73(11.3) 782 75(9.6) 1400 81(5.8) 894 45(5.0) 508 50(9.8) 7512 497(6.6)
2007 1390 110(7.9) 1486 134(9.3) 532 66(12.4) 835 74(8.9) 1262 83(6.6) 458 51(11.1) 404 50(12.4) 6367 568(8.9)
2006 1208 87(7.2) 1377 95(6.9) 368 60(16.3) 781 53(6.8) 1144 68(5.9) 215 49(22.8) 357 50(14.0) 5450 462(8.5)
2005 1108 60(5.4) 1195 75(6.3) 330 55(16.7) 734 59(8.0) 1008 58(5.8) 465 49(10.5) 356 50(14.0) 5196 406(7.8)
2004 902 50(5.5) 1152 96(8.3) 340 51(15.0) 620 53(8.6) 1065 64(6.1) 313 53(16.9) 322 50(15.5) 4714 417(8.9)
2003 715 50(7.0) 1097 78(7.1) 294 49(16.7) 527 59(11.2) 875 52(5.9) 179 53(29.6) 265 49(18.5) 3952 390(9.9)
2002 764 41(5.4) 1044 51(4.9) 227 46(20.3) 397 58(14.6) 593 51(8.6) 157 44(28.0) 207 50(24.2) 3389 341(10.1)
2001 681 52(7.6) 982 74(7.5) 144 46(31.9) 374 58(15.5) 545 50(9.2) 153 47(30.7) 380 50(13.2) 3259 377(11.6)
2000 587 50(8.5) 874 52(6.0) 106 48(45.3) 289 55(19.0) 461 50(10.9) 136 45(33.1) 318 50(15.7) 2771 350(12.6)
1999 532 50(9.4) 831 95(11.4) 139 52(37.4) 298 60(20.1) 392 49(12.5) 156 47(30.1) 242 50(20.7) 2590 403(15.6)
Total 9536 641(6.7) 11670 832(7.1) 3127 546(17.5) 5637 604(10.7) 8745 606(6.9) 3126 483(15.5) 3359 499(14.9) 45200 4211(9.3)
N* number of the actual breast cancer visits each year from year 1999-2008;
n** number of breast cancer cases collected per protocol.
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Variables by level Total distribution Clinical Stage I&II Clinical Stage III&IV ES vs. LS
P-value
(N = 4211) (N = 2554) (N = 901)
n%n% n %
Age at Diagnosis (Years)
(4211, 2554, 901)
Mean ± SD 48.7 ± 10.5 – 49.1 ± 10.4 – 48.8 ± 10.3 – 0.345
a
Range 21~86 – 21~86 – 21~85 –
≤ 29 80 1.9 38 1.5 17 1.9
30-39 710 16.9 404 15.8 144 16.0
40-49 1624 38.6 987 38.7 341 37.9 0.088
b
50-59 1147 27.2 693 27.1 276 30.6
≥ 60 650 15.4 432 16.9 123 13.7
Body Mass Index
(3281, 2107, 646 )
Mean ± SD 23.4 ± 3.3 – 23.3 ± 3.2 – 23.5 ± 3.4 – 0.173
a
Range 12.8~39.4 – 14.7~36.1 – 12.8~39.4 –
Underweight (≤ 18.49) 140 4.3 74 3.5 30 4.6
Normal Weight (18.50~24.99) 2217 67.6 1461 69.3 424 65.6 0.196
b
Overweight (25.00~29.99) 818 24.9 511 24.3 167 25.9
Obesity (≥ 30.00) 106 3.2 61 2.9 25 3.9
Occupation (3623, 2192, 796)
Housewife 173 4.8 127 5.8 26 3.3
Manual Worker 1893 52.3 1099 50.1 474 59.6 < 0.001
b
Mental Worker 1028 28.4 659 30.1 189 23.7
Others 529 14.6 307 14.0 107 13.4
Education (2091, 1315, 486)
None 186 8.9 112 8.5 55 11.3
Primary School 462 22.1 273 20.8 115 23.7
Middle School 606 29.0 370 28.1 141 29.0 0.008
b
High School 441 21.1 280 21.3 106 21.8
University and above 396 18.9 280 21.3 69 14.2
Marital Status (4193, 2548, 899)
Single 51 1.2 25 1.0 14 1.6
Married 4090 97.5 2482 97.4 878 97.7 0.073
b
Widowed/Divorced 52 1.2 41 1.6 7 0.8
Region (4211, 2554, 901)*
More Developed 1851 44.0 1127 44.1 389 43.2 0.620
b
Less Developed 2360 56.0 1427 55.9 512 56.8
Smoking History (4211, 2554, 901)
Never 2468 58.6 1451 56.8 596 66.2
Used 47 1.1 37 1.5 9 1.0 < 0.001
c
current 12 0.3 5 0.2 3 0.3
Unknown 1684 40.0 1061 41.5 293 32.5
Alcohol Drinking History
(4211, 2554, 901)
Never 2427 57.6 1415 55.4 598 66.4
Used 82 2.0 70 2.7 6 0.7 < 0.001
c
Now 13 0.3 7 0.3 4 0.4
Unknown 1689 40.1 1062 41.6 293 32.5
Li et al. BMC Cancer 2011, 11:364
http://www.biomedcentral.com/1471-2407/11/364
Page 5 of 11Table 2 General characteristics of breast cancer cases (Continued)
Breast Cancer Family History (4128, 2517, 882)
Yes 144 3.5 96 3.8 21 2.4 0.045
b
No 3984 96.5 2421 96.2 861 97.6
a Student’s t-test.
b Chi-square test.
c Fisher’s exact test.
* More Developed Regions: North, South, and East.
Less Developed Regions: North-East, Central, North-West, South-West..
Table 3 Reproductive characteristics of breast cancer cases
Variables by level Total distribution
(N = 4211)
Clinical Stage I&II
(N = 2554)
Clinical Stage III&IV
(N = 901)
ES vs. LS
P-value
n%n%n %
Menopausal Status
(4211, 2554, 901)
Pre-menopausal 2649 62.9 1585 62.1 541 60.0 0.285
b
Post-menopausal 1562 37.1 969 37.9 360 40.0
Age at Menopause (Years)
(1562, 969, 360) **
≤ 50 1017 65.1 631 65.1 239 66.4 0.665
b
> 50 545 34.9 338 34.9 121 33.6
Age at Menarche (Years)
(150, 80, 50)
7~11 3 2.0 0 0.0 2 4.0
12~13 37 24.7 22 27.5 11 22.0 0.200
c
≥ 14 110 73.3 58 72.5 37 74.0
Age at First Delivery (Years)
(2021, 1372, 357 )
< 20 33 1.6 15 1.1 11 3.1
20~24 917 45.4 638 46.5 153 42.9 0.030
b
25~29 940 46.5 632 46.1 166 46.5
≥ 30 131 6.5 87 6.3 27 7.6
Number of Live Births
(3947, 2428, 807)
0 99 2.5 44 1.8 17 2.1
1 1889 47.9 1177 48.5 348 43.1
2 1228 31.1 767 31.6 269 33.3 0.082
b
3 452 11.5 271 11.2 110 13.6
≥ 4 279 7.1 169 7.0 63 7.8
Breast Feeding History
(2671, 1754, 492)
Yes 2414 90.4 1591 90.7 445 90.5 0.861
b
No 257 9.6 163 9.3 47 9.5
O.C Consumption History
(4211, 2554, 901)
Never 543 12.9 376 14.7 98 10.9
Used 325 7.7 278 10.9 36 4.0 < 0.001
c
Now 11 0.3 10 0.4 1 0.1
Unknown 3332 79.1 1890 74.0 766 85.0
a Student’s t-test.
b Chi-square test.
c Fisher’s exact test.
** Median age of menopause has been used to create the two age-categories.
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istics of patients. The average mass size by CBE was 31.3
mm (s.d. = 17.8 mm) and patients in ES were more likely
to be examined of having masses less than 50 mm (P <
0.001) and had a much lower chance of having local inva-
sion (P < 0.001). Patients in LS were more likely to have
positive mammography results (P = 0.001) and positive
ultrasound diagnosis (P = 0.015). Over the 10 years, inva-
sive ductal carcinoma remained the dominant pathologic
subtype (86.5%). Among the 3,534 patients that had
estrogen receptor (ER) and progesterone receptor (PR)
information, less than 10% (9.5%) were only ER positive
and PR negative; 10.4% were positive with PR but nega-
tive with ER; about half (47.9%) were both ER and PR
Table 4 Clinical and pathologic characteristics of breast cancer cases
Variables by level Total distribution Clinical Stage I&II Clinical Stage III&IV ES vs.LS
P-value
(N = 4211) (N = 2554) (N = 901)
n%n% n %
Palpable Tumor Location by CBE(4211, 2554, 901)
Left 2189 52.0 1327 52.0 477 52.9
Right 1995 47.4 1213 47.5 419 46.5 0.868
c
Non-palpable 27 0.6 14 0.5 5 0.6
Mass Size by CBE
(3555, 2434, 825)
Mean ± SD 31.3 ± 17.8 – 27.7 ± 12.8 – 40.7 ± 23.4 – < 0.001
a
Range 0~250 – 0~150 – 0~250 –
< 50 mm 3036 85.4 2247 92.3 559 67.8
≥ 50 mm 519 14.6 187* 7.7 266 32.2 < 0.001
b
Local Invasion
(3663, 2428, 826)
Yes 183 5.0 45 1.9 106 12.8 < 0.001
b
No 3480 95.0 2383 98.1 720 87.2
Mammography Diagnosis (1275, 877, 286)**
Positive 1094 85.8 750 85.5 266 93.0 0.001
b
Negative 181 14.2 127 14.5 20 7.0
Ultrasound Diagnosis (2253, 1629, 409 )**
Positive 2006 89.0 1461 89.7 383 93.6 0.015
b
Negative 247 11.0 168 10.3 26 6.4
Postoperative Pathological Diagnosis (4014, 2540, 877)
Carcinoma in Situ(CIS) 143 3.6 77 3.0 5 0.6
Invasive Ductal
Carcinoma
3471 86.5 2203 86.7 801 91.3 < 0.001
c
Other Type Invasive
Carcinoma
385 9.6 252 9.9 69 7.9
Others 15 0.3 8 0.3 2 0.2
ER/PR Status
(3534, 2316, 758)
ER+&PR+ 1691 47.9 1148 49.6 340 44.9
ER+&PR- 337 9.5 204 8.8 84 11.1 0.070
b
ER-&PR+ 367 10.4 230 9.9 86 11.4
ER-&PR- 1139 32.2 734 31.7 248 32.7
HER-2 Status
(2849, 1935, 582)
HER-2 + 736 25.8 504 26.0 154 26.5 0.842
b
HER-2 - 2113 74.2 1431 74.0 428 73.5
a Student’s t-test.
b Chi-square test.
c Fisher’s exact test.
* Among the 187 women with palpable lumps ≥ 50 mm by CBE, 101 were found to have smaller lumps based on the postoperative evaluation and were
categorized as stage I or stage IIA (16 as stage I; 85 as stage IIA). The rest 86 were categorized as stage IIB..
** Negative: negative, benign, and possibly benign finding; Positive: malignant suspicious, malignant.
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mation was available for 2,849 patients and the majority
(74.2%) of them were HER-2 negative (Table 4). Among
the 4,211 cases, the majority (60.6% (2,554/4,211)) had
ES breast cancer, and less than a quarter (21.4% (901/
4,211)) had LS disease. About 18% (756/4,211) of cases
did not have staging information. The stage distribution
differed between the less developed and more developed
regions of China (P < 0.001). More stage I patients
(19.9%) were presented in more developed regions than
that (12.7%) in less developed regions and the reverse
was seen for stage IV patients (Table 5).
Treatment Patterns
Among all breast cancer cases, the majority (96.9%
(4,078/4,211)) had undergone surgery procedures and
radical mastectomy was the predominant option (88.8%
(3,740/4,211). A minority of women (5.5% (231/4,211))
received breast conservative surgery. Chemotherapy was
the second most important treatment option (81.4%
(3,428/4,211) for breast cancer patients in China. By
comparison, radiotherapy (22.6% (952/4,211)) and endo-
crine therapy (38.0% (1,599/4,211)) were not as popular
as surgery and chemotherapy (Table 6).
Discussion
This was the first geographically representative epidemio-
logic study of breast cancer in China and included more
than 4,000 patients over its course. This study, via its
inclusion of a large number of sites across all seven tradi-
tional regions of China, facilitated a thorough assessment
of breast cancer patient characteristics, treatment alloca-
tion, and allowing a unique analysis of possible regional
variations in these aspects of breast epidemiology and
management across the entirec o u n t r y .I ta l s oh e l p st o
determine levels of unmet medical need and identify
regions of high risk for breast cancer within China.
All patients included in our study were ethnically
Chinese. Their clinical characteristics were significantly
different from those of the women in western countries.
The mean age at diagnosis was 48.7 years, and this was
similar to the findings from other regional studies within
China [9-14]. It was also in agreement with reports from
other Asian countries such as Singapore, India and also
similar to Saudi Arabia, all of which were around the mid-
40s. This was about a decade earlier than what is reported
for Western Caucasian women [15-19]. The reasons for
the distinctions remain obscure, but four hypotheses may
explain. First, older Asians including Chinese women had
been less exposed to estrogen related risk factors thus
have been less susceptible to breast cancer than their
younger counterparts. Second, younger women were more
genetically predisposed to breast cancer. Third, younger
women were more aware of breast cancer. They have
broader access to medical care as there is no nationwide
organized screening program in China as well as in the
majority of the modernizing Asian countries. Fourth,
mammography has been used among older women in the
population based mammography screening in Western
countries. This may partly account for why breast cancer
clusters peak around 60-69 years in Western countries.
In this study, 60.6% of the patients had early stage breast
cancer and 21.4%% had late stage disease. The incidence
of early stage disease on presentation was lower than the
data from China Tianjin (72.3%) [14], Taiwan (78.3%) [13]
and Singapore (79%) [20], and much lower than the wes-
tern countries such as the United States (85%) [21]. A
study from Hong Kong which focused on a selected group
of affluent Chinese patients reported an 88.9% of early
stage cases [19]. While in the African countries, large pro-
portions of patients presenting at late stage were reported,
early stage cases accounted for only 9.27% to 42.7%
[22-25]. The vast difference between regions and countries
may due to the absence of a nationwide breast cancer
screening program in developing countries including
China, whereas such programs are fully or partly imple-
mented in the majority of developed countries [26]. The
findings of our study also suggest that women who were
mental workers and had at least a university education
were more likely to present breast cancer at early stage.
Table 5 Stage distribution of breast cancer cases by region
Clinical
Stage
Total More Developed Regions** Less Developed Regions*** P*
North South East Sub-total Northeast Central North-West South-West Sub-total
N %N%N%N%N%N %N% N % N % N %
Stage I 663 15.7 172 26.8 98 16.2 95 15.7 365 19.9 131 15.8 73 13.4 77 15.9 17 3.4 298 12.7
Stage II 1891 44.9 280 43.7 243 40.2 239 39.4 762 41.6 323 38.8 400 73.3 170 35.2 236 47.3 1129 48.3
Stage III 788 18.7 93 14.5 117 19.4 152 25.1 362 19.8 119 14.3 53 9.7 127 26.3 127 25.5 426 18.2 < 0.001
Stage IV 113 2.7 2 0.3 20 3.3 5 0.8 27 1.5 4 0.5 3 0.6 56 11.6 23 4.6 86 3.7
Unknown 756 18.0 94 14.7 126 20.9 115 19.0 335 18.3 255 30.7 17 3.1 53 11.0 96 19.2 421 18.0
* Stage distribution in more developed regions vs. less developed regions.
** More Developed Regions: North, South, and East.
***Less Developed Regions: Northeast, Central, North-West, South-West.
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Page 8 of 11This is in consistent with reports from a review article that
socioeconomic disparities including low family income,
poor educational attainment and impaired access to
healthcare etc were related to the more advanced disease
at diagnosis and poorer prognosis [27].
ER positive breast cancers are acknowledged to be
related to a better prognosis than those that are ER nega-
tive [28] as they respond better to hormone therapy [29].
HER-2 positive breast cancers are more aggressive and
require more expensive therapy [30]. In our study, 57.4%
(2,028/3,534) were ER positive and 25.8% (736/2,849)
were HER-2 positive. The ER status of Chinese breast
cancer was documented previously and the positivity var-
ied from 45.3% to 67% [31-35]. When compared with
data from developed countries, the positivity from our
study is significantly lower [36,37]. The prevalence of
HER-2 has been documented to be 27.9% in a Chinese
study [35] and 15% in one study from the United States
[38]. It suggests that breast cancer in Chinese women
m a yb em o r ea g g r e s s i v et h a nt h o s ei nt h ed e v e l o p e d
countries, but those differences may also be explained by
the un-uniformed tests used, different cut-off value
referred, and bias from the age distribution in various
studies. Although our study sample is representative, the
tests were done retrospectively and different methods
and protocols were conducted. Further study using a
representative sample and standard protocol to under-
stand the status of ER/PR/HER-2 status in Chinese breast
cancer is necessary and would make it more comparable.
Surgery was the most common treatment in Chinese
female breast cancer patients followed by chemotherapy.
Among all surgery procedures, radical mastectomy was
widely perceived as the only curative treatment, which is
consistent with a study from Hong Kong [39]. Options
for radiotherapy and endocrine therapy were much less,
which indicates that adjuvant therapy, especially radio-
therapy and endocrine therapy are of great unmet
needs. Further analysis and studies were necessary to
understand the patterns of treatment based on detailed
information of treatment indications such as tumor size,
lymph node involvement, final margins, and ER status.
These findings will need to be considered in light of the
study’s strengths and weaknesses. The primary strengths
of this study are (1) the large number of patients included
and (2) the geographic representativeness of the included
sites. The main potential study limitations are (1) selection
bias may exist in the catchment of breast cancer patients
in the selected hospitals as no less elite hospitals as com-
parison were selected from the same regions. (2) There is
no comparison group to compare the risk factors of devel-
oping breast cancer and (3) data quality is dependent on
the thoroughness of the clinician’s documentation of med-
ical history, treatment, and outcomes.
Conclusion
The Chinese breast cancer multi-center clinical epide-
miologic study represents the first geographically repre-
sentative study of breast cancer in China to understand
patterns of breast cancer characteristics, therapy use and
knowledge of continuing unmet needs for breast cancer
by retrospectively reviewing the existed clinical data.
The younger age of breast cancer onset among Chinese
women and more advanced tumor stages pose a great
challenge for Chinese government on breast cancer con-
trol. The higher proportion of ER+/PR+ breast cancer
patients is a great challenge for breast cancer management
in China. The Government oriented campaign to raise
awareness will need to be expanded and continued. The
most updated clinical guideline will also need to be disse-
minated to doctors at all levels to benefit the patients, ulti-
mately improving the prognosis in Chinese breast cancer
patients.
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